<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792087</url>
  </required_header>
  <id_info>
    <org_study_id>SMKV-011-CP3</org_study_id>
    <nct_id>NCT03792087</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SmofKabiven Peripheral Versus Compounded Emulsion</brief_title>
  <official_title>Efficacy and Safety of SmofKabiven Peripheral [Multi-oil Fat Emulsion (C6-24)/Amino Acids (16)/Glucose (13%) and Electrolyte Injection] Versus Compounded Emulsion: A Randomized, Active-Controlled, Open-Labelled, Multi-Centre Study in Adult Surgical Patients Requiring Parenteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present protocol describes a randomized, open-labelled study in which either SmofKabiven
      Peripheral or a hospital compounded control Parenteral Nutrition (PN) regimen will be given
      to adult surgical patients for 5 consecutive days. As serum prealbumin is a well-established
      surrogate efficacy parameter reflecting the patient´s nutritional status, the absolute change
      of the serum prealbumin level at the day of the final study visit compared to baseline will
      represent the primary efficacy parameter in the present study. In addition, other variables
      will be assessed in this study, i.e., C-reactive Protein (CRP), free fatty acids, immunology
      parameters, taurine, comparison of the time required for Total Parenteral Nutrition (TPN)
      preparation of the two groups, the results of physical examination, vital signs, relevant
      nutrition- and safety-related laboratory parameters in venous blood and urine, the results of
      an Electrocardiography (ECG), and the number, severity, seriousness, clinical relevance,
      relatedness and outcome of Adverse Events (AEs). The aim of the planned study is to
      demonstrate that SmofKabiven Peripheral is not inferior to the comparative drug (compounded
      emulsion).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Prealbumin</measure>
    <time_frame>6 days</time_frame>
    <description>Change in Serum Prealbumin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (CRP)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linoleic acid</measure>
    <time_frame>6 days</time_frame>
    <description>Change in linoleic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linolenic acid</measure>
    <time_frame>6 days</time_frame>
    <description>Change in linolenic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arachidonic acid</measure>
    <time_frame>6 days</time_frame>
    <description>Change in arachidonic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eicosapentaenoic acid (EPA)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in EPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Docosahexaenoic acis (DHA)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in DHA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboxane B3 (TXB3)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in TXB3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboxane B2 (TXB2)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in TXB2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin (IL)-1</measure>
    <time_frame>6 days</time_frame>
    <description>Change in IL-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-2</measure>
    <time_frame>6 days</time_frame>
    <description>Change in IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>6 days</time_frame>
    <description>Change in IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation 4 (CD4) /Cluster of Differentiation 8 (CD8)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in CD4/CD8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma amino acid (taurine)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in plasma amino acid (taurine)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Coded according to Medical Dictionary for Regulatory Affairs (MedDRA) by System Organ Class (SOC) and preferred term</description>
  </other_outcome>
  <other_outcome>
    <measure>Local intolerance for peripherally infusion</measure>
    <time_frame>6 days</time_frame>
    <description>Reported as AE</description>
  </other_outcome>
  <other_outcome>
    <measure>Development of phlebitis</measure>
    <time_frame>6 days</time_frame>
    <description>Reported as AE</description>
  </other_outcome>
  <other_outcome>
    <measure>Development of thrombophlebitis</measure>
    <time_frame>6 days</time_frame>
    <description>Reported as AE</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Body temperature</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of head to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of mouth to to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of nose, to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of throat to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination tonsils to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of ears to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of eyes to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of neck to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Palpation of lymph nodes to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Auscultation of lungs and chest to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Palpation of breasts to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of cardiovascular system to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of abdomen to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of musculoskeletal to identify medically significant aberrance (according to standard of care following the discretion of the treating physician)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of skin to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of genitalia to identify medically significant aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of neurological system to identify medically significant aberrance (according to standard of care following the discretion of the treating physician)</description>
  </other_outcome>
  <other_outcome>
    <measure>Red blood cell (RBC) count</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Total white blood cell (WBC) count</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Haemoglobin (Hb)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Haematocrit (Hct)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelets</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Creatinine</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Urea</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Sodium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Potassium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnesium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Total calcium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Chloride</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Phosphate</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Aspartate aminotransferase (AST)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Alanine aminotransferase (ALT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Alkaline phosphatase (AP)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Gamma-glutamyl transpeptidase (γ-GT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Lactate dehydrogenase (LDH)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Total and direct bilirubin</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumin</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Total protein</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Cholesterol</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Triglycerides</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Low Density Lipoprotein (LDL)-C</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>High Density Lipoprotein (HDL)-C</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Activated partial thromboplastin time (APTT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>Prothrombin time (PT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>International Normalised Ratio (INR)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variables</description>
  </other_outcome>
  <other_outcome>
    <measure>power of hydrogen (pH) value</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Bilirubin</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Protein</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>WBC</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>RBC</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Ketone body</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Electrocardiogram to assess cardiac disorders (e.g. Myocardial infarction, Pericarditis, QT interval Prolongation, etc.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Preparation time</measure>
    <time_frame>5 days</time_frame>
    <description>Comparison of the time required for TPN preparation for the two groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Parenteral Feeding</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>SmofKabiven Peripheral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous intravenous Infusion for SmofKabiven Peripheral via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital compounded emulsion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous intravenous Infusion for Hospital compounded emulsion via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SmofKabiven Peripheral</intervention_name>
    <description>Total Parenteral Nutrition</description>
    <arm_group_label>SmofKabiven Peripheral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hospital compounded emulsion</intervention_name>
    <description>Total Parenteral Nutrition</description>
    <arm_group_label>Hospital compounded emulsion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is scheduled to undergo elective abdominal surgery

          2. Female or male patient, age between 18 and 75 years (inclusively)

          3. Postoperatively, patient is expected to receive 100% of the total daily energy demand
             via PN for at least 5 consecutive days

          4. Body Mass Index (BMI) ≥ 16 and ≤ 30 kg /m2, and actual body weight ≥ 40 kg

          5. Patient is capable to give Informed Consent, agrees to participate in the study, and
             signs the Informed Consent Form

        Exclusion Criteria:

          1. Patient has received PN or parenteral amino acids in the last 10 days before
             randomization (exception: administration of glucose will be allowed)

          2. Severe liver insufficiency or AST, ALT or total bilirubin at least 1.5-times higher
             than the upper limit of normal range

          3. International Normalised Ratio (INR) at least 1.5 times higher than the upper limit of
             normal range

          4. Uncontrolled hyperglycaemia, fasting blood glucose &gt; 180 mg/ dl (10 mmol/L)

          5. Severe renal impairment defined as serum creatinine value at least 1.5 times higher
             than the upper limit of normal range

          6. Serious hyperlipidaemia (serum cholesterol and/or triglycerides and/or LDL-C level at
             least 1.5 times higher than the upper limit of normal range)

          7. Inborn abnormality of amino acid metabolism

          8. Present signs of acute pancreatitis, hypothyroidism or hyper-thyroidism as diagnosed
             clinically

          9. Serum level of any of the electrolytes (sodium, potassium, magnesium, total calcium,
             chloride, phosphate) above the upper limit of the normal range

         10. Known unstable metabolism (e.g., known metabolic acidosis)

         11. Known hypersensitivity to fish-, egg-, soybean, or peanut protein or to any of the
             active substances or excipients of the study drugs

         12. General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration,
             and decompensated cardiac insufficiency /congestive heart failure

         13. Unstable conditions (e.g., acute myocardial infarction, stroke, embolism, severe
             sepsis, shock)

         14. Drug abuse and/or chronic alcoholism

         15. Psychiatric diseases, epilepsy

         16. Administration of growth hormones within the previous 4 weeks before surgery, or
             chronic maintenance therapy with systemic glucocorticoids 4 weeks before surgery

         17. Participation in a clinical study with an investigational drug or an investigational
             medical device within one month prior to start of study or during study

         18. Patient is pregnant or lactating and intends to continue breast-feeding

         19. Development of intraoperative/ postoperative conditions (assessed after surgery and
             before enrollment of patients):

               1. Intra-operative blood loss &gt; 1000ml;

               2. Development of a condition in which PN is contraindicated;

               3. Intra- or postoperative urine output &lt;0.5 ml/kg/h;

               4. Need for postoperative haemo-filtration or dialysis;

               5. Contraindication or inability to obtain peripheral or central venous catheter
                  access;

               6. Intra-operative decision on limited treatment, e.g. due to diagnosis of
                  carcinomatosis;

               7. Intra-operative severe complications including resuscitation, hemorrhagic and
                  septic shock, acute single and multiple organ dysfunction including pulmonary,
                  hepatic, and renal dysfunction prohibiting early postsurgical extubation,
                  requiring liver-specific treatment and renal replacement therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu Guohao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Friendship Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002925.pdf</url>
    <description>International Council for Harmonisation (ICH) E10 'Note for Guidance on Choice of Control Group', July 2000</description>
  </link>
  <reference>
    <citation>Calder PC. n-3 fatty acids, inflammation, and immunity--relevance to postsurgical and critically ill patients. Lipids. 2004 Dec;39(12):1147-61. Review.</citation>
    <PMID>15736910</PMID>
  </reference>
  <reference>
    <citation>Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, Seeger W, Grimminger F. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med. 2003 May 15;167(10):1321-8. Epub 2003 Feb 25.</citation>
    <PMID>12615625</PMID>
  </reference>
  <reference>
    <citation>Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ. NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L84-9. Epub 2002 Aug 30.</citation>
    <PMID>12388359</PMID>
  </reference>
  <reference>
    <citation>Pluess TT, Hayoz D, Berger MM, Tappy L, Revelly JP, Michaeli B, Carpentier YA, Chioléro RL. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 2007 May;33(5):789-797. doi: 10.1007/s00134-007-0591-5. Epub 2007 Mar 22. Erratum in: Intensive Care Med. 2007 Jul;33(7):1310. Intensive Care Med. 2007 Jul;33(7):1310.</citation>
    <PMID>17377770</PMID>
  </reference>
  <reference>
    <citation>Xiong J, Zhu S, Zhou Y, Wu H, Wang C. Regulation of omega-3 fish oil emulsion on the SIRS during the initial stage of severe acute pancreatitis. J Huazhong Univ Sci Technolog Med Sci. 2009 Feb;29(1):35-8. doi: 10.1007/s11596-009-0107-3. Epub 2009 Feb 18.</citation>
    <PMID>19224159</PMID>
  </reference>
  <reference>
    <citation>Helmut Grimm, A balanced lipid emulsion—A new concept in parenteral nutrition. Clinical Nutrition Supplements (2005) 1, 25-30.</citation>
  </reference>
  <reference>
    <citation>Grimm H, Mertes N, Goeters C, Schlotzer E, Mayer K, Grimminger F, Fürst P. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr. 2006 Feb;45(1):55-60. Epub 2005 Jul 22.</citation>
    <PMID>16041475</PMID>
  </reference>
  <reference>
    <citation>Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep;250(3):395-402. doi: 10.1097/SLA.0b013e3181b36657.</citation>
    <PMID>19661785</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR, Puder M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul;118(1):e197-201.</citation>
    <PMID>16818533</PMID>
  </reference>
  <reference>
    <citation>Alwayn IP, Gura K, Nosé V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar;57(3):445-52. Epub 2005 Jan 19.</citation>
    <PMID>15659701</PMID>
  </reference>
  <reference>
    <citation>Boulétreau P, Chassard D, Allaouchiche B, Dumont JC, Auboyer C, Bertin-Maghit M, Bricard H, Ecochard R, Rangaraj J, Chambrier C, Schneid C, Cynober L. Glucose-lipid ratio is a determinant of nitrogen balance during total parenteral nutrition in critically ill patients: a prospective, randomized, multicenter blind trial with an intention-to-treat analysis. Intensive Care Med. 2005 Oct;31(10):1394-400. Epub 2005 Aug 24.</citation>
    <PMID>16132885</PMID>
  </reference>
  <reference>
    <citation>Sergi G, Coin A, Enzi G, Volpato S, Inelmen EM, Buttarello M, Peloso M, Mulone S, Marin S, Bonometto P. Role of visceral proteins in detecting malnutrition in the elderly. Eur J Clin Nutr. 2006 Feb;60(2):203-9.</citation>
    <PMID>16234837</PMID>
  </reference>
  <reference>
    <citation>Shenkin A. Serum prealbumin: Is it a marker of nutritional status or of risk of malnutrition? Clin Chem. 2006 Dec;52(12):2177-9.</citation>
    <PMID>17138848</PMID>
  </reference>
  <reference>
    <citation>Young GA, Hill GL. Assessment of protein-calorie malnutrition in surgical patients from plasma proteins and anthropometric measurements. Am J Clin Nutr. 1978 Mar;31(3):429-35.</citation>
    <PMID>415592</PMID>
  </reference>
  <reference>
    <citation>Young GA, Collins JP, Hill GL. Plasma proteins in patients receiving intravenous amino acids or intravenous hyperalimentation after major surgery. Am J Clin Nutr. 1979 Jun;32(6):1192-9.</citation>
    <PMID>87126</PMID>
  </reference>
  <reference>
    <citation>Young GA, Hill GL. A controlled study of protein-sparing therapy after excision of the rectum: effects of intravenous amino acids and hyperalimentation on body composition and plasma amino acids. Ann Surg. 1980 Aug;192(2):183-91.</citation>
    <PMID>6773484</PMID>
  </reference>
  <reference>
    <citation>Chinese medical clinical guidelines parenteral enteral nutrition 2008, edited by Chinese Medical Association, People's Medical Publishing House.</citation>
  </reference>
  <reference>
    <citation>Bernstein LH. The systemic inflammatory response syndrome C-reactive protein and transthyretin conundrum. Clin Chem Lab Med. 2007;45(11):1566-7; author reply 1568-9.</citation>
    <PMID>17970714</PMID>
  </reference>
  <reference>
    <citation>SSPC. Intralipid 20%, Summary of Product Characteristics, dated 14 February 2007</citation>
  </reference>
  <reference>
    <citation>SSPC. Novamin 11.4%, Summary of Product Characteristics, dated 01 December 2013</citation>
  </reference>
  <reference>
    <citation>McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B, Ochoa JB, Napolitano L, Cresci G; A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2009 May-Jun;33(3):277-316. doi: 10.1177/0148607109335234.</citation>
    <PMID>19398613</PMID>
  </reference>
  <reference>
    <citation>Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F; ESPEN. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr. 2009 Aug;28(4):378-86. doi: 10.1016/j.clnu.2009.04.002. Epub 2009 May 21.</citation>
    <PMID>19464088</PMID>
  </reference>
  <reference>
    <citation>Chowdary KV, Reddy PN. Parenteral nutrition: Revisited. Indian J Anaesth. 2010 Mar;54(2):95-103. doi: 10.4103/0019-5049.63637.</citation>
    <PMID>20661345</PMID>
  </reference>
  <reference>
    <citation>Singer P, Berger MM, Van den Berghe G, Biolo G, Calder P, Forbes A, Griffiths R, Kreyman G, Leverve X, Pichard C, ESPEN. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr. 2009 Aug;28(4):387-400. doi: 10.1016/j.clnu.2009.04.024. Epub 2009 Jun 7.</citation>
    <PMID>19505748</PMID>
  </reference>
  <reference>
    <citation>Fresenius Kabi. SomfKabiven Peripheral, emulsion for infusion. Summary of Product Characteristics, dated September.29. 2009</citation>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SmofKabiven</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Parenteral</keyword>
  <keyword>Abdominal surgery</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

